The encouraging evidence from pilot studies of tamoxifen used as an alternative to surgery in elderly, frail patients [11,14] led to prospective randomized clinical trial designed to evaluate the role of tamoxifen vs (vs) surgery in old patients, whose characteristics are recapitulated in Table 1, Section A. The trial from Robertson and colleagues enrolled 137 patients with operable hormone receptor positive (HR+) breast cancer, who received tamoxifen 40 mg per day or surgery. The gene discussed is NR4A1; the disease is breast carcinoma.